Terminated due to poor accrual and without sufficient patients or data to report on any outcomes.

To determine the efficacy of soy/isoflavone supplementation on hot flashes in men who are being treated with luteinizing hormone-releasing hormone (LHRH) agonist therapy for control of advanced prostate cancer

Literature has shown that low dose estrogens can control hot flashes in men on androgen deprivation but with a high risk of thromboembolic events. Soy derivatives that contain isoflavones, a type of phytoestrogen, have been evaluated in peri-menopausal women as a possible safer alternative to synthetic estrogens but there has not been a similar study performed on their effect in men on androgen deprivation therapy for prostate cancer.

Inclusion Criteria:

• Histologically proven adenocarcinoma of prostate with treatment of prostate cancer (radical prostatectomy, radiation therapy, etc.)
• had biochemical/clinical relapse and started on antiandrogens
• have documented history of hot flashes

Exclusion Criteria:

• History of MI, DVT, CVA
• peanut allergy
• untreated hypothyroidism
• must be off other medical treatment for hot flashes for 2 weeks before enrollment in this study

This trial was stopped early due to low enrollment. There was not a sufficient number of participants to accurately analyze the data. Randomization was not completed prior to termination. Data for population analysis not collected.

Early termination due to low accrual. Insufficient number of participants for accurate analysis. No data collected.